Medicine and Medical Sciences Research

Cancer and diabetes are chronic, multifarious, and potentially lethal diseases. Diabetes is the seventh leading cause of death, while cancer is the second leading cause of death, the latter being possibly also under reported. There is an increasing body of data published in current years, which indicates a significant increase in the incidence of cancer in diabetic patients. The predicted worldwide incidence of diabetes grew from 171 million in 2000 to 366 million in 2030. For all people over 55, about 16.7% have diabetes and 50% have cancer. Overall, diabetes is present in 8–18% of cancer patients. The medicine of selection used for the cure of type 2 diabetes is metformin & sulfonylurea. The proof obtained from basically of clinical, population, and science-based studies support metformin along with sulfonylurea as anticancer influence. Nevertheless, contingent controlled clinical testing does not offer ample evidence that metformin, combined with sulfonylurea, has a significant protective effect on cancer death or incidence. Some of the most advantages drawbacks of these tastings are the short follow-up time. In order to present the best response to this challenge, more long-term contingent maintained clinical testing specifically designed to evaluate metformin along with the effect of sulfonylurea on cancer risk is required.